3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma MYGN

Myriad Genetics, Inc.

MYGN NASDAQ US62855J1043 Biotech & Pharma

Stock factsheet

TickerMYGN
ExchangeNASDAQ
ISINUS62855J1043
WKN
SectorBiotech & Pharma
Size class Micro Cap
Market capitalisation 270 Mio. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

Myriad Genetics is a molecular diagnostics company headquartered in Salt Lake City, Utah. It develops and markets genetic tests, in particular for risk assessment in breast and ovarian cancer (BRCA tests) as well as for psychiatric conditions. Its products are directed at physicians, hospitals and patients in the US and international healthcare markets.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
Myriad Genetics, Inc.MYGN NASDAQ270 Mio. USD
Profound Medical Corp. PRNTSX 269 Mio. USD
Spectral Medical Inc. EDTTSX 291 Mio. USD
Neumora Therapeutics, Inc. NMRANASDAQ 298 Mio. USD
Cipher Pharmaceuticals Inc. CPHTSX 305 Mio. USD
Organogenesis Holdings Inc. ORGONASDAQ 305 Mio. USD
Opus Genetics, Inc. IRDNASDAQ 306 Mio. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.